Appeal No. 1996-1748
Application 07/747,670
(b) a surrogate promoter and surrogate tissue-specific enhancer operatively linked to
said HIV DNA; and
(c) a polyadenylation signal operatively linked to said HIV DNA.
17. A process for preparing a DNA for expression of a non-infectious, substantially
complete HIV RNA, wherein said DNA comprises a complete HIV genome except in having
deleted therefrom the 5'-LTR, a portion of the 5' leader and a portion of the 3'-LTR, said process
comprising:
(a) providing in a first DNA fragment a non-infectious HIV DNA which is a complete HIV
genome except in having deleted therefrom the 5'-LTR sequence, a portion of the 5' leader
sequence and a portion but not all of the 3'-LTR;
(b) operably linking to the 5' end of said HIV genome a surrogate promoter and a
surrogate tissue-specific enhancer comprised in a second DNA fragment;
(c) operably linking to the 3' and of said HIV genome a polyadenylation signal comprised
in a third DNA fragment; and
(d) ligating said operably linked fragments of (a), (b), and (c) into a vector for expression
of said non-infectious HIV genome in a cell.
The references relied upon by the examiner are:
Leder et al. (Leder) 4,736,866 Apr. 12, 1988
Southern et al. (Southern), “Transformation of Mammalian Cells to Antibiotic Resistance with a
Bacterial Gene Under Control of the SV40 Early Region Promoter,” Journal of Molecular and
Applied Genetics, Vol. 1, pp. 327-41 (1982).
Ratner et al. (Ratner), “Complete nucleotide sequence of the AIDS virus, HTLV-III,” Nature, Vol.
313, pp. 277-84 (Jan. 1985).
Fisher et al. (Fisher), “A molecular of HTLV-III with biological activity,” Nature, Vol. 316,
pp. 262-65 (July 1985).
2
Page: Previous 1 2 3 4 5 6 Next
Last modified: November 3, 2007